Education
About Us
Working with TipRanks
Follow Us
Oramed Pharmaceuticals Inc (ORMP)
:ORMP
ORMP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.82 - $3.09
Previous CloseN/A
Volume63.61K
Average Volume (3M)63.77K
Market Cap
$85.77M
Enterprise Value-$23.59M
Total Cash (Recent Filing)$142.30M
Total Debt (Recent Filing)$429.00K
Price to Earnings (P/E)21.1
Beta0.74
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding40,845,085
10 Day Avg. Volume68,741
30 Day Avg. Volume63,772
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.95
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
InvestmentThe joint venture will receive a significant capital infusion, with HTIT committing a notable $70M investment, supplemented by a $20M investment from Oramed.
Joint VentureOramed entered into a definitive agreement with HTIT, marking a milestone in the creation of a joint venture centered around Oramed’s cutting-edge oral drug delivery technology.
Bears Say
Clinical EfficacyThe candidates in Oramed's pipeline have yet to show definitive clinical proof-of-concept efficacy.
Oramed Pharm News
ORMP FAQ
What was Oramed Pharmaceuticals Inc’s price range in the past 12 months?
Oramed Pharmaceuticals Inc lowest stock price was $1.82 and its highest was $3.09 in the past 12 months.
What is Oramed Pharmaceuticals Inc’s market cap?
Oramed Pharmaceuticals Inc’s market cap is $85.77M.
When is Oramed Pharmaceuticals Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Oramed Pharmaceuticals Inc’s earnings last quarter?
Oramed Pharmaceuticals Inc released its earnings results on Jan 11, 2024. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.12 by $0.04.
Is Oramed Pharmaceuticals Inc overvalued?
According to Wall Street analysts Oramed Pharmaceuticals Inc’s price is currently Overvalued.
Does Oramed Pharmaceuticals Inc pay dividends?
Oramed Pharmaceuticals Inc does not currently pay dividends.
What is Oramed Pharmaceuticals Inc’s EPS estimate?
Oramed Pharmaceuticals Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oramed Pharmaceuticals Inc have?
Oramed Pharmaceuticals Inc has 40,845,085 shares outstanding.
What happened to Oramed Pharmaceuticals Inc’s price movement after its last earnings report?
Oramed Pharmaceuticals Inc reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.12. Following the earnings report the stock price went down -0.4%.
Which hedge fund is a major shareholder of Oramed Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ORMP
Oramed Pharm Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.48%
12-Months-Change
Fundamentals
Return on Equity
-18.37%
Trailing 12-Months
Asset Growth
-27.55%
Trailing 12-Months
Company Description
Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Technical Analysis
Ownership Overview
18.79% Insiders
0.38% Mutual Funds
16.00% Other Institutional Investors
64.00% Public Companies and
Individual Investors